J.D. Kleinke’s Post

Let's talk about disrupting the status quo in the prescription drug pricing industry. Forward-thinking players are shaking up how middlemen operate, and it’s encouraging to see this shift across the board. Marc Cuban, for example, is bypassing wholesalers and taking direct control. Innovative PBMs, like Abarca, are gaining traction with major players like Blue Shield of California So what does this all mean for the consumer? Our CEO, Umar Afridi, will take the stage at Asembia on Tuesday, April 30 at 1:00 PM to tackle this complex topic. Stop by his panel, “From Opaque to Transparent: Transforming the Way We Pay For Drugs,” and let us know what you think in the comments below. #asembia24 #DigitalHealth #HealthcareInnovation #ConsumerHealthcare #HealthcareTechnology #Healthtech #pharma #pharmacy

In her latest article, Elena Meurer dives deep into the complexities of manufacturing targeted medicines on a global scale 🌍 Discover how companies navigate diverse regulatory frameworks, ensure product quality, and manage the intricate balance between customization and standardization. Read more to explore the strategies and insights that can help manufacturers overcome these challenges and deliver maximum benefit to patients. 🔗 https://lnkd.in/g4J3bM7w #Pharma #TargetedMedicines #Healthcare #RegulatoryAffairs #QualityControl #PharmaLex

With the AMCP Market Insights program, you can easily compare trends, best practices, and benchmarks across various disease states. This comprehensive information prepares you for downstream changes, including regulatory impacts, quality considerations, and legal aspects. Explore detailed reports to help manage costs of new expensive specialty drugs and optimize resource allocation. Learn more: https://bit.ly/44eSgjf #managedcare #pharmacy

The #InfectiousDiseaseDiagnostics market is predicted to surge 6.61% by 2032. Get the insights on the market trends now with this professional report: http://ow.ly/OhL150OCUNz #Pharma #Healthcare

See our latest blog on the impact of biosimilars on the Humira drug market. Discover how these alternatives are driving down costs for patients and clients, making health care more affordable and accessible. Read it here: https://bit.ly/3Rh3L4E #Pharmacy #HealthCare

The #InfectiousDiseaseDiagnostics market is predicted to surge 6.61% by 2032. Get the insights on the market trends now with this professional report: http://ow.ly/OhL150OCUNz #Pharma #Healthcare

I swear some of these companies are the GLP-1s of our American healthcare economics. Engineered solutions to a problem of our own making, available for a monthly subscription. I don’t know how we get to a place of reform when we praise tech “solutions” that layer complexity on top of a fundamentally broken system to achieve what they think of as “transparency,” which really is not. Here’s a good line— “…GoodRx, perhaps the most successful innovator in the prescription drug pricing transparency space…” I don’t know whether to laugh or barf. #pharmacy #pharmacist #healthcare #drugpricing #monopoly #pbm #pharma #bigpharma https://lnkd.in/g7PGJjkX

On 19 April, the Health Resources and Services Administration published a final rule in the Federal Register adopting several changes to the current administrative dispute resolution process under the 340B Drug Pricing Program. Read our insights here. https://lnkd.in/eaXjmTmu #health #pharma #drugpricing

Don't miss our annual Pharma 50 issue from Pharmaceutical Executive! Including my insightful interview with Mark Cuban where he speaks about the necessity for transparency in #drugpricing and Mark Cuban Cost Plus Drug Company, PBC — give it a read!

In her latest article, Elena Meurer dives deep into the complexities of manufacturing targeted medicines on a global scale 🌍 Discover how companies navigate diverse regulatory frameworks, ensure product quality, and manage the intricate balance between customization and standardization. Read more to explore the strategies and insights that can help manufacturers overcome these challenges and deliver maximum benefit to patients. 🔗 https://lnkd.in/dmfd4P8R #Pharma #TargetedMedicines #Healthcare #RegulatoryAffairs #QualityControl #PharmaLex